Thomas Schuetz: Positive Tovecimig Study Data, Looking Forward to Meeting with FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CMPX?
"We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with BTC have no approved therapeutic option in the second line setting. Tovecimig, with its strong response rate, striking progression benefit and impact on overall survival would be a compelling treatment alternative for these patients," said Thomas Schuetz, Chief Executive Officer and Vice Chairman of the Board of Directors."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPX
Wall Street analysts forecast CMPX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.830
Low
8.00
Averages
12.67
High
24.00
Current: 1.830
Low
8.00
Averages
12.67
High
24.00
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
- Financial Performance: Compass Therapeutics reported a Q1 2026 GAAP EPS of -$0.10, aligning with market expectations, indicating stability in financial management despite ongoing losses.
- Cash Position: As of March 31, 2026, the company held $195 million in cash and marketable securities, down from $209 million on December 31, 2025, representing a $14 million decrease; however, the anticipated cash runway extends into 2028, ensuring operational stability.
- Cash Usage in Operations: During the first quarter, Compass utilized $18 million in net cash for operating activities, partially offset by $4 million from common stock exercises, reflecting ongoing investments in R&D and operations.
- Market Reaction: Despite positive secondary endpoint results from the COMPANION-002 study, the stock price of Compass Therapeutics fell due to missing the overall survival endpoint, indicating market caution regarding its long-term potential.
See More
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
- Clinical Trial Results: In a Phase 2/3 study of biliary tract cancer patients, the combination of tovecimig and paclitaxel demonstrated a progression-free survival (PFS) of 4.7 months, significantly better than the 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), indicating tovecimig's potential as a new second-line treatment option.
- FDA Meeting Planned: Tovecimig received Orphan Drug Designation in April 2026, and the company plans to meet with the FDA prior to its Biologics License Application (BLA) submission, paving the way for market access to address the urgent needs of biliary tract cancer patients.
- Financial Position: As of Q1 2026, the company reported $195 million in cash and marketable securities, expected to fund operations into 2028, although this reflects a decrease from $209 million at the end of 2025, highlighting ongoing investments in R&D.
- R&D Progress: Clinical trials for CTX-8371 and CTX-10726 are underway, with the former showing deep responses in three cancer types and initial data from the latter expected in Q4 2026, further enhancing the company's competitive edge in oncology therapeutics.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Compass Therapeutics for potential securities fraud or unlawful business practices by its officers, which could undermine investor confidence and lead to legal repercussions.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met the key secondary endpoint of progression-free survival in a phase 2/3 study for biliary tract cancer treatment, but failed to meet the overall survival endpoint, indicating mixed results.
- Stock Price Plunge: Following this announcement, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market disappointment over the clinical trial outcomes.
- Potential Legal Consequences: The investigation by Pomerantz LLP, a prominent firm in securities class action litigation, may lead to class action lawsuits against Compass, exacerbating the company's trust crisis among investors and impacting its future financing and market performance.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
- Clinical Trial Setback: Compass Therapeutics' biliary tract cancer candidate tovecimig missed a key secondary endpoint—overall survival—in a phase 2/3 study, resulting in a ~66% drop in stock price on Monday.
- Crossover Patient Impact: The COMPANION-002 study showed 54% of patients crossed over to the treatment group, complicating results; crossover patients had a median overall survival of 12.8 months compared to 6.1 months for non-crossover patients, indicating data complexity.
- Secondary Endpoint Achieved: While overall survival was not met, the combination of tovecimig and paclitaxel achieved a median progression-free survival of 4.7 months versus 2.6 months for placebo, indicating some efficacy.
- Financial Performance: Compass Therapeutics reported a GAAP EPS of -$0.09, reflecting financial pressure from R&D and clinical trials, suggesting investors need to exercise patience for potential future opportunities.
See More
Compass Therapeutics Reports Q1 Results with Cash Runway Until 2028
- Financial Performance: Compass Therapeutics reported a Q1 2026 GAAP EPS of -$0.10, aligning with market expectations, indicating stability in financial management despite ongoing losses.
- Cash Position: As of March 31, 2026, the company held $195 million in cash and marketable securities, down from $209 million on December 31, 2025, representing a $14 million decrease; however, the anticipated cash runway extends into 2028, ensuring operational stability.
- Cash Usage in Operations: During the first quarter, Compass utilized $18 million in net cash for operating activities, partially offset by $4 million from common stock exercises, reflecting ongoing investments in R&D and operations.
- Market Reaction: Despite positive secondary endpoint results from the COMPANION-002 study, the stock price of Compass Therapeutics fell due to missing the overall survival endpoint, indicating market caution regarding its long-term potential.
See More
Tovecimig Shows Significant Survival Benefit in Biliary Tract Cancer Trial
- Clinical Trial Results: In a Phase 2/3 study of biliary tract cancer patients, the combination of tovecimig and paclitaxel demonstrated a progression-free survival (PFS) of 4.7 months, significantly better than the 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), indicating tovecimig's potential as a new second-line treatment option.
- FDA Meeting Planned: Tovecimig received Orphan Drug Designation in April 2026, and the company plans to meet with the FDA prior to its Biologics License Application (BLA) submission, paving the way for market access to address the urgent needs of biliary tract cancer patients.
- Financial Position: As of Q1 2026, the company reported $195 million in cash and marketable securities, expected to fund operations into 2028, although this reflects a decrease from $209 million at the end of 2025, highlighting ongoing investments in R&D.
- R&D Progress: Clinical trials for CTX-8371 and CTX-10726 are underway, with the former showing deep responses in three cancer types and initial data from the latter expected in Q4 2026, further enhancing the company's competitive edge in oncology therapeutics.
See More
Pomerantz LLP Investigates Compass Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Compass Therapeutics for potential securities fraud or unlawful business practices by its officers, which could undermine investor confidence and lead to legal repercussions.
- Clinical Trial Results: On April 27, 2026, Compass announced that its drug tovecimig met the key secondary endpoint of progression-free survival in a phase 2/3 study for biliary tract cancer treatment, but failed to meet the overall survival endpoint, indicating mixed results.
- Stock Price Plunge: Following this announcement, Compass's stock price fell by $3.24, or 64.41%, closing at $1.79 per share on April 27, 2026, reflecting market disappointment over the clinical trial outcomes.
- Potential Legal Consequences: The investigation by Pomerantz LLP, a prominent firm in securities class action litigation, may lead to class action lawsuits against Compass, exacerbating the company's trust crisis among investors and impacting its future financing and market performance.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
Compass Therapeutics Shares Plunge 66% After Clinical Trial Setback
- Clinical Trial Setback: Compass Therapeutics' biliary tract cancer candidate tovecimig missed a key secondary endpoint—overall survival—in a phase 2/3 study, resulting in a ~66% drop in stock price on Monday.
- Crossover Patient Impact: The COMPANION-002 study showed 54% of patients crossed over to the treatment group, complicating results; crossover patients had a median overall survival of 12.8 months compared to 6.1 months for non-crossover patients, indicating data complexity.
- Secondary Endpoint Achieved: While overall survival was not met, the combination of tovecimig and paclitaxel achieved a median progression-free survival of 4.7 months versus 2.6 months for placebo, indicating some efficacy.
- Financial Performance: Compass Therapeutics reported a GAAP EPS of -$0.09, reflecting financial pressure from R&D and clinical trials, suggesting investors need to exercise patience for potential future opportunities.
See More
